Conventional cancer therapies involve the systemic delivery of anticancer agents that neither discriminate between cancer and normal cells nor eliminate the risk of cancer recurrence. Here, we demonstrate that the combination of gene, drug and phototherapy delivered through a prophylactic hydrogel patch leads, in a colon cancer mouse model, to complete tumour remission when applied to non-resected tumours and to the absence of tumour recurrence when applied following tumour resection. The adhesive hydrogel patch enhanced the stability and provided local delivery of embedded nanoparticles. Spherical gold nanoparticles were used as a first wave of treatment to deliver siRNAs against Kras, a key oncogene driver, and rod-shaped gold nanoparticles mediated the conversion of near-infrared radiation into heat, causing the release of a chemotherapeutic as well as thermally induced cell damage. This local, triple-combination therapy can be adapted to other cancer cell types and to molecular targets associated with disease progression.
C
ancer is the leading cause of mortality worldwide, with over 10 million new cases every year in Europe and the US. It is estimated that 3 million new cases will be diagnosed with 1.7 million deaths each year 1 . The need for the development of more effective cancer diagnostics and therapeutics is imperative. In fact, dire consequences pursue the massive investment in cancer therapy and in particular drug development, unlike the progress in treating other chronic diseases, resulting in high mortality each year worldwide. Colorectal cancer (CRC) is the second most common cause of cancer death among men and women in Europe, as stated by the World Health Organization. It is the third most common cancer found in the US, as specified by the American Cancer Society and the National Cancer Institute. After breast cancer, CRC is the second most common cancer in women and the third most frequent in men, after lung and prostate cancer. Overall, the lifetime risk of developing CRC is about 1 in 20 (ref. 2) .
Surgery, referred to as colectomy or a segmental resection, is often the main treatment for early and late stage CRC. A reasonable proportion of CRC patients remain clinically remissive for months or years following tumour resection and chemotherapy. However, after this stage of remission, tumours recur in 30-50% of all cases, generally presenting metastasis. Moreover, surgery is fraught with many complications including bleeding at the surgical site, the formation of blood clots in the legs, and damage to nearby organs. Leakage from the anastomotic site is another complication that may lead to infection, delaying further treatment. Compromised healing following surgery may lead to scar tissue and bowel obstruction along with tissue adhesions 3 . Previous therapies for CRC have not provided sufficient specificity and structural guidance to promote tumour inhibition after remission and the full regeneration of the injured intestinal tissue after surgery. Conventional cancer therapy involves the use of anti-neoplastic agents that do not significantly distinguish between cancer and normal cells 4 . Efficient in vivo uptake to cancer cells requires better targeting moieties to improve cellular uptake and reduced toxicity to contiguous normal cells, towards reduced systemic toxicity and undesired side effects 5 . This is where nanotechnology comes into play. Nanotechnology has immensely progressed in the last 20 years to supply important advances in early diagnosis and prevention, bioimaging, multifunctional therapies, and potent gene and drug delivery systems [6] [7] [8] [9] [10] . Here, we developed a hydrogel patch for local CRC treatment using triple-combination therapy: gene, drug and phototherapy. We hypothesized that a multi-modal approach is necessary to efficiently abrogate the tumour. Efficacious gene and drug delivery along with tumour ablation by phototherapy was achieved by coating the colorectal tumour with an adhesive hydrogel scaffold 11 made of oxidized dextran and poly(amidoamine) G5 dendrimer that we have shown are capable of enhancing the stability of doped nanoparticles used for local drug and gene delivery 6, 12, 13 . We previously reported on the contextual performance of dendrimer/dextran adhesive hydrogel when applied to tissues with underlying pathology compared with healthy tissues and how to exploit tissue microenvironmental characteristics to inform rational material design 11, 14, 15 . We now aim to take these precision biomaterials a step further, where materials are not only designed to attain predictive performance in pathological environments, but are used to attain complete tumour regression and reverse diseasespecific traits to prompt selective and personalized therapies.
By developing a combination therapeutic approach that considers the tissue microenvironment in material design, we can achieve disease-responsive materials promoting selective uptake, oncogene modulation, drug release in cancer cells, and selective phototherapy promoting tumour ablation, thus minimizing side effects. This modular platform is based on two waves of treatment; the knockdown of important genes in cancer progression followed by the delivery of a potent drug to stop cancer cell proliferation in several stages of the disease following triggered drug release with near-infrared (NIR) phototherapy. We demonstrate that this platform can be used as a prophylactic hydrogel patch to prevent cancer recurrence, and/or as a neoadjuvant therapy to shrink tumours before resection, thus eliminating the need for resection.
The design of local triple-combination therapy
Our specific goal and overall hypothesis was that the development of a hydrogel-based patch doped with nanoparticles for in vivo local triple therapy, gene/drug delivery combined with phototherapy, would synergistically abrogate tumours and prevent their recurrence, either with or without tumour resection. Platform efficacy was examined in an in vivo mouse model of CRC. A tunable hydrogel patch impregnated with drug-and siRNAnanoparticle conjugates (drug-gold nanorods and short interfering RNA (siRNA)-gold nanospheres) for local gene and drug release in colorectal tumour cells was designed (Fig. 1a) . Nanoparticles (that is, gold nanorods) were functionalized with biomolecules that target unique or overexpressed biomarkers in tumour cells (tumour-targeting moieties) to enhance the uptake of gold nanorods in cancer cells. Gold nanorods, having the capacity to convert NIR radiation into heat causing localized release and tumour ablation [16] [17] [18] , were functionalized with the Food and Drug Administration (FDA)-approved monoclonal antibody, bevacizumab or Avastin, that blocks the vascular endothelial growth factor (VEGF) pathway in CRC 19 . Bevacizumab (Avastin) neutralizes VEGF and blocks its signal transduction through VEGFR-1 and VEGFR-2 receptors, as demonstrated by the inhibition of VEGF-induced cell proliferation, survival, permeability, nitric oxide production, migration and tissue factor production 20 . By inhibiting VEGFR activity we were able to block the endogenous expression of VEGF and to reduce the amount of secreted VEGF 20 . The particles will release the drug (Avastin) and produce heat following laser irradiation to kill remaining cancer cells. TCP-1 peptide (N-CTPSPFSHC-C), which is commonly used to target the vasculature of orthotropic CRC patients 21 and specifically targets CRC cells, was conjugated to the nanorods and the nanospheres to provide preferential uptake in cancer cells. Gold nanospheres were used in conjunction with the nanorods to deliver siRNAs that silence a major oncogene driver in CRC progression-Kras (Kirsten rat sarcoma viral oncogene homolog). Kras is an effector molecule responsible for signal transduction in CRC and approximately 30-50% of colorectal tumours are known to have a mutated Kras gene 22 . To enhance the siRNA uptake, the gold nanospheres were functionalized with an HA1 peptide (in addition to TCP-1), a fusogenic peptide (influenza haemagglutinin-HA1 peptide, N-YPYDVPDYA-C 23 ) that destabilizes the endosomal membrane stimulating endosomal discharge by a pH-responsive machinery.
Concerning the physico-chemical properties of the final nanoconjugates, the siRNA/nanoparticle ratio for the gold nanospheres was 105:1 and the Avastin (drug)/nanoparticle ratio for the gold nanorods was 15:1 (see Supplementary Table 1 ). The mean particle diameter of the siRNA-gold nanospheres was 32.7 (±1.9) nm, and 35.6 (±2.1) nm for the drug-gold nanorods, as measured by dynamic light scattering (DLS). Both siRNA-gold nanospheres −29.4 (±5.2) mV and drug-gold nanorods −23.1 (±3.8) mV are anionic as measured by the zeta potential.
Implantable dendrimer-dextran hydrogels will be doped with the drug-gold nanorods (Fig. 1b) and siRNA-gold nanospheres (Fig. 1c) to afford local drug/gene delivery and hyperthermia. Since delivery of these potent effector molecules will be preferentially achieved in tumoral cells, only minor damage to surrounding cells if at all should be conceivable, thus diminishing unnecessary death of surrounding healthy tissue. Extensive quantification (Supplementary Figs 1-4) , stability ( Supplementary Fig. 5 ) and characterization assays (Supplementary Figs 6 and 7) were conducted for the functionalized nanoconjugates.
To enable local release to diseased tissue while avoiding material migration and release to adjacent sites, the hydrogel was decorated with aldehyde groups (provided by the oxidized dextran) that interact with tissue amines to form adhesive bonds 15, 24 . The adhesive architecture was evaluated by high-resolution scanning electron microscope (SEM, Fig. 1d) images. In addition to the SEM images, we performed an energy-dispersive X-ray spectroscopy map-scanning analysis of the hydrogel doped with both drug-gold nanorods and siRNA-gold nanospheres to evaluate their elemental composition, especially the gold content, which pointed at a uniform particle distribution throughout the hydrogel (Fig. 1e) .
Functional characterization and in vitro performance
Gold nanorods provide us with an efficacious photothermal tumour therapy 25, 26 . Hence, we evaluated the photothermal performance of gold nanorods when embedded in our hydrogel as a prophylactic thermal patch. It is well known that gold nanorods with 40 × 10 nm present an absorbance peak in the NIR (around 800 nm), whereas gold nanospheres with 20 nm diameter have a surface plasmon resonance peak around 530 nm (Fig. 2a) . Therefore, we envisioned that when irradiated in the NIR range, only the gold nanorods would transduce electromagnetic radiation into heat. To evaluate the thermal effects of both gold nanorods and gold nanospheres using a NIR laser light source (808 nm, 1 W) and their potential to serve as photothermal probes in vivo, the temperature of gold nanorods and gold nanospheres (Fig. 2b) Tumour volumes were monitored and on day 15 hydrogels were implanted. NIR treatment was applied at days 18, 19, 20 and 25 using a 808 nm laser at 1 W for 120 s. Mice were monitored in the following weeks for survival and tumour profiling. c, Fluorescence and thermographic images of the hydrogels doped with drug-gold nanorods, siRNA-gold nanospheres or their combination (n = 5). d, Thermographic surveillance of photothermal heating in mice (n = 5)
implanted with hydrogels doped with drug-gold nanorods, siRNA-gold nanospheres or their combination, 72 h after the first NIR treatment.
s (808 nm, 1 W) resulted in a 50
• C rise in temperature, with no variation in temperature in the gold nanosphere solution following the same irradiation power. These results clearly demonstrate that the synthesized gold nanorods experience substantial thermal effects at low laser energy irradiation.
We then focused on examining the effect of siRNA-nanospheres on cancer cells' biochemical activity. At 24, 48 and 72 h posttransfection, quantitative PCR (qPCR) data confirmed a reduction in Kras expression with increasing amounts of siRNA-nanospheres (Fig. 2c) . qPCR amplification of messenger RNA extracted from CRC cells (Lovo-6-Luc human colorectal adenocarcinoma cells) following treatment with siRNA-nanospheres confirmed the efficient RNA interference (RNAi) mechanism, as depicted by the decrease in target gene expression following treatment with siRNA-nanospheres. siRNA-nanospheres functionalized with the fusogenic peptide HA1 are more efficient in downregulating Kras, confirming the peptide function in enhancing nanosphere uptake and hence siRNA availability in the cytoplasm.
To corroborate the triggered conjugated drug release following heat-up of gold nanorods in cells, drug release was quantified as a function of increasing laser exposure time. Nearly 95% of the Avastin was released from the gold nanorods after 120 s of laser exposure (Fig. 2d) . Studying the Avastin release mechanism ( Supplementary Fig. 8 ) revealed that following NIR laser application the drug is being released while remaining conjugated to the PEG. Yet, the exposure to increasing temperatures following laser irradiation, under a range of exposure times, and the drug attachment to the PEG do not affect Avastin activity in Lovo-6-Luc human CRC cells ( Supplementary Fig. 9 ).
To evaluate cellular uptake, confocal microscopy was performed in Lovo-6-Luc CRC cells treated with the combination of DY647-labelled siRNA-nanospheres and Alexa Fluor 555-labelled druggold nanorods. Both siRNA-nanospheres and drug-nanorods have a high cellular uptake efficiency at 24 h post-incubation ( Fig. 2e and Supplementary Fig. 10 ). Confocal imaging showed strong stability of both nanospheres and nanorods and efficient entry into the target CRC cells, when compared with the low cellular uptake in healthy 3T3 human fibroblasts. These results clearly demonstrate that both nanoparticles exhibit enhanced cellular uptake in cancer cells when conjugated to the TCP-1 peptide, when compared with healthy cells 21 . A live-dead assay of CRC cells following uptake of 10 nM of spheres, rods or the combination of spheres and rods 24 h after laser application (Fig. 2f) or following increased exposure time to both nanoparticles was performed. This assay was conducted as previously described 13 using a double staining procedure with acridine orange and propidium iodide representing green and red fluorescence for live and dead cells, respectively. As shown in Fig. 2f only drug-gold nanorods or the combination of rods and spheres results in a vast cell death (>95%) 24 h after laser application, due to the combination of local heat and consequent drug (Avastin) release.
To validate Avastin release from the gold nanorods and evaluate the efficacy of the drug in blocking VEGF, qPCR was performed with mRNA extracted from cells in the same conditions as described above for the viability assays (Supplementary Fig. 11a) . Notably, only the cells that were treated with gold nanorods carrying Avastin were able to inhibit VEGF expression 48 h after the application of an 808 nm laser light source for 120 s.
The tumorigenicity of the CRC cells was evaluated by measuring the IC 50 via an MTT assay ( Supplementary Fig. 11b ) following treatment with gold nanorods with and without drug and before or 24 and 48 h after laser irradiation. Gold nanorods with Avastin significantly inhibited CRC cell proliferation when compared with cells that were only laser irradiated or cells that were incubated with gold nanorods alone, without Avastin.
Local therapy improves cancer therapeutic e cacy
Next, we proceeded to study the in vivo nanoconjugates' pharmacokinetics and platform therapeutic efficacy in a CRC mouse model. The efficacy of the triple-therapy-based therapeutic platform was compared with gene, photo or chemotherapy alone and with or without the application of a NIR laser source. All therapeutic combinations, single, double or triple therapy, were performed with the same concentration of siRNA or drug and at the same therapeutic regimen.
Hydrogel scaffolds loaded with the specific therapeutic nanoconjugates were implanted adjacent to the colorectal tumour of SCID hairless congenic mice (CB17.Cg-Prkdc scid Hr hr /IcrCrl) when tumours reached a volume of ∼100 mm 3 . In a combinatory wave of treatments, we were able to first knockdown an important gene in cancer progression. In a second wave of treatment, we delivered a potent drug to stop cancer cell proliferation following triggered drug release with NIR application, with concomitant tumour ablation using local phototherapy (Fig. 3a,b) .
To form a hydrogel, 12.5% poly(amidoamine) G5 dendrimer (25% amines) solution was mixed with nanoparticle-containing 5% dextran aldehyde solution (drug-gold nanorods and/or siRNAgold nanospheres were at a final concentration of 10 nM each). Drug-gold nanorod and siRNA-gold nanosphere scaffolds showed complete release within 24 h ( Supplementary Fig. 12 ) under physiological conditions in vitro (pH 7.4 and 37
• C). These therapeutic hydrogels loaded with specific nanoconjugates for each therapy were monitored by fluorescence and thermographic imaging (Fig. 3c) .
Having observed the hydrogels' photothermal efficiency (Fig. 3c) , their ability to serve as powerful optical nanoantennas for photothermal tumour heating 72 h after NIR application was subsequently investigated (Fig. 3d) . Hydrogel alone, hydrogel doped with drug-gold nanorods or siRNA-gold nanospheres or their combination (rods and spheres) was implanted into mice-bearing colorectal tumours. Temperatures above 60
• C occurred only in irradiated tumours containing hydrogels doped with drug-gold nanorods or rods and spheres together (Fig. 3d) , whereas hydrogel alone or hydrogel doped with siRNA-gold nanospheres displayed maximum surface temperatures of around 33
• C.
Tumour regression and recurrence prevention
The capability of the triple therapy to shrink the tumour before its resection or prevent tumour recurrence following resection was evaluated in two separate mouse groups; hydrogel containing both drug-gold nanorods and siRNA-gold nanospheres was implanted on top of the tumour before its resection or at the tumour site following resection as a wash-out procedure. Inhibition of tumour progression was measured by luciferase expression, as previously described 6 , while nanoconjugates' release (drug-gold nanorods in green and siRNA gold nanospheres in red) was tracked fluorescently (Fig. 4a ) via a live imaging system for 15 days after hydrogel implantation and 10 days after the first NIR application.
Nanoconjugate uptake was quantified using intermittent fluorescence imaging of live mice for 15 days post-implantation, and their biodistribution by the fluorescent signal of excised organs (liver, kidneys, spleen, heart, lungs and intestines) (Fig. 4a for triple-therapy groups and Supplementary Figs 13-15 for all other treatment combinations). No fluorescent signal was detected in any of the major organs. All nanoconjugates accumulate exclusively in the tumour tissue as demonstrated by the ex vivo images of the organs ( Fig. 4a and Supplementary Figs 13-15) .
When the patch was used as a prophylactic measure following tumour resection, complete remission was achieved (Fig. 4a,c) . Even when the tumour was not resected, application of the hydrogel patch resulted in tumour abrogation as evident by bioluminescence imaging (more than 90%, n = 5, P < 0.001) 15 days after hydrogel implantation, eliminating the need for resection (Fig. 4a,b) . We found that 40% of the tumours recurred following resection in the absence of further treatment (hydrogel alone control group), while the triple-therapy hydrogels implanted post-resection were able to completely destroy the remaining cancer cells, thus preventing tumour re-growth (Fig. 4a,c and Supplementary Fig. 16 ). This effect was perpetual as 170 days after tumour resection there was still no evidence for tumour recurrence in the triple-therapy hydrogel group (Supplementary Fig. 16 ). When comparing the efficacy of single, dual or triple therapy (that is, single therapy: chemotherapy, gene therapy or phototherapy; dual therapy: gene therapy and chemotherapy, chemotherapy and phototherapy or gene therapy and phototherapy; or triple therapy: chemotherapy, gene therapy and phototherapy), the triple therapy is far more efficacious than the other therapies or their combinations thereof (Fig. 4d) . Irrespective of treatment modality, phototherapy add-on resulted in increased nanoparticle accumulation in the tumour both for nanorods and for nanospheres, as was quantified by their respective fluorescence signal in mouse tissues using a live imaging system at day 15 after single, dual or triple therapy (Supplementary Fig. 17 ). The combination of relatively instantaneous killing of cancer cells following phototherapy with high accumulation of nanoparticles containing drug/gene may result in a 'higher effective dose' of the cargo per cell, which further contributes to tumour abrogation.
To further demonstrate the superiority of the triple-therapy local hydrogel patch, the efficacy of the local delivery was compared with systemic (tail-vein injection) or intratumoral administration of the nanoparticles alone, with drug-gold nanorods and/or siRNA-gold nanospheres at a final concentration of 10 nM each ( Supplementary  Figs 18 and 19) . We found that while the local administration of a hydrogel patch doped with triple-therapy combination resulted in more than 90% tumour shrinkage (Fig. 4d) , only 60% or 40% tumour reduction was attained following intratumoral and systemic administration of the same therapy combination, respectively ( Supplementary Fig. 19b ), leading to poor survival increments (36 days after tumour induction for systemic therapy, 41 days for intratumoral injection and at least 150 days for the local hydrogel therapy, see Supplementary Fig. 19c ). Systemic administration of the nanoparticles results in nonspecific accumulation in the kidneys, spleen and liver ( Supplementary Fig. 19a ). These results provide convincing evidence that the hydrogel patch is instrumental to the achievement of superior therapeutic performance.
To validate the safety of the hydrogel patches mice organs were harvested 15 days after hydrogel implantation and H&E stained for histopathology (Supplementary Fig. 20) . H&E staining revealed that in vivo application of hydrogel alone or the triple-therapy hydrogels did not cause any organ damage (that is, lung, liver, kidney, spleen, heart, intestine), when compared with the control group (without hydrogel treatment). Nevertheless, the tumour tissue shows extensive reduction in vascularization, in accordance with tumour size reduction following treatment. No signs of in vivo toxicity nor other physiological complications were observed in any of the animals for 15 days after hydrogel exposure as indicated by the preservation of steady body weight (Supplementary Fig. 21 ), pointing at hydrogel biocompatibility. respectively. a, Live imaging of SCID hairless congenic mice with colorectal tumour xenografts implanted with hydrogels that are embedded with drug-gold nanorods and siRNA-gold nanospheres with NIR treatment, either with no tumour resection or after tumour resection (n = 5 per group). Ex vivo images of tumours and whole body organs (T, tumour; Lv, liver; K, kidneys; S, spleen; H, heart; Lu, lung; Int, intestines) are also depicted. b,c, Tumour burden following treatment as measured by luciferase activity, without tumour resection (b) and after tumour resection (c) (n = 5, statistical analysis was performed using two-way analysis of variance, * * * , P < 0.001). Errors are reported as standard deviation (s.d.). d, Tumour burden of mice treated with gene therapy (siRNA-gold nanospheres), chemotherapy (drug-gold nanorods), phototherapy (gold nanorods) or double (chemo + gene, gene + photo, chemo + photo) and triple therapy (gene, chemo and phototherapy combination) (n = 5, statistical analysis performed with two-way analysis of variance, * * * , P < 0.001), as measured by luciferase activity. Errors are reported as standard deviation (s.d.). e, Kaplan-Meier curves for mice treated with hydrogel sca olds for gene therapy (siRNA-gold nanospheres), chemotherapy (drug-gold nanorods), phototherapy (gold nanorods) or triple therapy (gene therapy, chemotherapy and phototherapy combination). Statistical analysis (n = 5) was performed with a Log-Rank Mantel-Cox test (P = 0.008). Survival cuto criteria included tumour ulceration or compassionate euthanasia, when the aggregate tumour burden >1 cm in diameter, or if the tumour impeded eating, urination, defecation or ambulation. f, Immunohistochemical evaluation of Ki67 for tumours treated with hydrogels alone or following triple therapy (gene therapy, chemotherapy and phototherapy combination). g, Histopathology and biodistribution analyses of tumour tissue from mice treated with triple-therapy combination for several time points (from 6 h to 15 days) (blue, nucleus, DAPI; red, RNAi nanospheres, DY647; green, antibody-drug nanorods, Alexa Fluor 555). Scale bars, 100 µm. Quantification of nanoparticle percentage distribution over time was calculated using unity-based normalization. FEN1  ZNF527  SNORD8  PGR  BARD1  DOK5  LIX1  NPIPA1 ⁄⁄⁄ NPIPA…  MGC24103  SLC15A1  SNRPN ⁄⁄⁄ SNURF  GRIK1  RPS6KA6  HMGN2P46  SORCS3  GOLIM4  LINC00943  MYH11  FPGT-TNNI3K ⁄⁄⁄ …  GGTA1P  ICAM2  FSTL5  PCDHB15  TRIM44  BANK1  ZNF594  CLIP2  IFIT1  LEPR ⁄⁄⁄ LEPROT  TMEM163  KRT34 ⁄⁄⁄ LOC10…  SWAP70  DOCK3  UBASH3B  ARHGEF28  BCL6  MCC  INPP5B  RRM2B   TRDMT1  ZNF555  RWDD2A  DEPDC7  PHF5A  MICAL3  LOC10…  CHSY3  HNRNP…  FHAD1  DEFB1…  GIMAP7  CCDC1…  MMP19  EPHA5  CALD1  KLRC1  HORM…  CD200…  RGS18  ANKRD…  FKBP9P1  TM4SF18  HMGN2…  LOC10…  CYLC2  SOX5  PXDNL  POTEG…  BOLL  STK32B  GPR63  ACOT12  DCAF11  KLRAP1  ABCA1…  TRPM3  LOC10…  TCR-al…   PKIA  ZSWIM7  DDO  TMEM27  C1GALT1  SEPP1  SLC38A6  HBG1  CRBN  FCGRT  HSD17B2  ARX  ZNRD1- Survival study was performed for mice following triple therapy (gene therapy, chemotherapy and phototherapy combination) or control single therapies (gene therapy: siRNA-gold nanospheres; chemotherapy: drug-gold nanorods; or phototherapy: gold nanorods). Significant high mouse survival advantage followed triple therapy compared with hydrogel alone, or the single-therapy groups (Fig. 4e) (P = 0.008, 100% survival for at least 170 days).
SPC25
Survival follows the same trend seen with tumour size reduction following the different treatment modalities (see Fig. 4a ). This data are of utmost importance since patients that present with CRC will undergo surgery to resect the tumour and in more advanced stages undergo chemotherapy, but still carry the risk of recurrence owing to remaining cells at the tumour resection site that will continue to proliferate 27, 28 . Immunohistochemical analysis showed that Ki67 expression, which is a cellular marker exclusively linked with cell proliferation, was considerably reduced following local triple therapy when compared with the hydrogel-alone group (Fig. 4f) . Histologically, both drug-gold nanorods (in green) and siRNAgold nanospheres (in red) were able to accumulate efficiently throughout the tumour tissue over time (Fig. 4g) . Interestingly, nanorods present with more substantial accumulation early (peak at 6 h, 92.4 ± 2.3% accumulation) followed by nanosphere accumulation (peak at 72 h, 99.2 ± 2.7% accumulation).
These findings corroborate the results seen in Fig. 4a , where all nanoconjugates accumulate exclusively in the tumours.
Tumour genetic profile in response to single local therapy
Following assessment of therapeutic efficacy, we studied the tumour genetic profile of treated mice since the gene expression profile of a cell determines its phenotype as well as its response to various factors, including drugs, irradiation or gene modulators 29 . To understand host response to local administration of the therapeutic hydrogel doped with nanoparticles, colorectal tumour gene expression profiles in mice were generated using a GeneChip PrimeView Human Gene expression array. These arrays contain more than 530,000 probes housing over 36,000 transcripts and variants, which reproduce more than 20,000 genes that are plotted through RefSeq or via UniGene annotation. For gene expression heat maps, the average expression across three independent replicates in each condition based on the probes with the maximum signal intensity per gene was calculated.
A clustergram of genes that are differentially expressed following the application of hydrogel scaffolds for gene therapy (siRNA-gold nanospheres), chemotherapy (drug-gold nanorods) or phototherapy (gold nanorods) in mice was generated (Supplementary Fig. 22a ). The data were analysed by unsupervised hierarchical clustering, which showed that the three treatment groups had distinct gene expression profiles. Using a threefold change relative to the sham group (that is, treatment with hydrogel alone) as a benchmark for differential expression, numerous genes were derived from the different therapeutic modalities. Responders (that is, phototherapy) were clustered separately from non-responders (gene therapy and chemotherapy) and untreated samples (that is, sham). For the clustering of differentially expressed genes, a total of 20,087 genes were analysed and an absolute log 2 fold change of ≥1 with an adjusted p value of ≤0.05 to define the differentially expressed gene sets was used. For the correlation between the untreated group and the phototherapy group the number of differential genes is 2,943, for the gene-therapy groups 959 and for the chemotherapy group 380 genes ( Supplementary  Fig. 22a ). The volcano plots for the different therapies were assembled by plotting the negative log of the p value on the y axis. Highly deregulated genes appear further to the left and right sides, whereas highly significant changes appear higher on the plot (Supplementary Fig. 22) .
To identify the relationship between the four ordered sets of treatments (in this case, gene expression data for several different therapies and for the untreated group-sham) a Pearson correlation matrix was developed (Supplementary Figs 22b and 24 ). This matrix indicates both how the four sets are related and the strength of that relationship. All replicates correlate very well (the diagonal of the heat map), and all different therapy samples show a very high correlation (>0.95).
To evaluate which genes are up-or downregulated in response to the different treatments we created a set with log 2 fold-change cutoff of ≥2 and realized a hierarchical clustering of these differentially expressed gene sets, using a row-normalized data-set that was prepared using the broad GenePattern tool Pre-process Dataset 30 ( Fig. 5a ).
This analysis enables pinpointing distinct gene expression fluctuations related to phototherapy with several clusters of genes that were only suppressed or induced in these groups (Fig. 5a ). For example, phototherapy-treated tumours showed substantial suppression of a large cluster of genes that are involved in cytoskeleton remodelling and cell adhesion via integrin-mediated cell adhesion or involved in cell proliferation and differentiation such as MYH11 (myosin heavy chain). However, a large cluster of genes was induced only in the phototherapy-treated tumours. This cluster contains genes mainly involved in metabolism such as RRM2B (ribonucleotide reductase M2 B), or in immune response mechanisms such as Bcl-6 (B-cell CLL/lymphoma 6).
Concerning gene therapy, the major difference is the presence of a large cluster that is repressed in response to treatment. This includes genes mainly involved in protein folding, membrane trafficking and signal transduction, such as ABCA1 (ATP-binding cassette, subfamily A).
We also found that the response to chemotherapy was associated with the depletion of several genes related to metabolism such as ADH6 (alcohol dehydrogenase 6) or in cell adhesion and migration processes such as FN1 (fibronectin).
Using an alternative clustering/filtering, we selected the top 25 largest absolute fold-change genes for each of the three therapy groups, and then summarized the selection into a string. Briefly, YesYesYes would be top 25 in all three therapy groups, YesNoNo is the top 25 in phototherapy groups but not in gene therapy or chemotherapy groups (Supplementary Fig. 25 ). These results revealed that there are 59 genes that are top 25 in at least 1 therapy group. Most importantly, this analysis revealed that several microRNA (miRNAs; that is, miR-17, miR-18A, miR-19A, miR-19B1, miR-20A and miR-92A1) are downregulated in all therapy groups, whereas in the control group (sham) they are all upregulated. These miRNAs are part of the miR-17∼92 cluster, which encrypts for six individual miRNAs: miR-17, miR-18A, miR-19A, miR-20A, miR-19B1 and miR-92A1. The miR-17∼92 miRNA cluster is positioned on human chromosome 13q31.3, in a genomic region that is frequently activated in lymphomas and other types of cancer 31 . The mature miRNAs encoded by this locus are highly expressed in cancer cells promoting cell proliferation and blocking apoptosis 32 and have key roles in cancer progression due to their capability of suppressing the expression of numerous tumourassociated proteins 33 . Supervised Gene Ontology (GO) and detailed Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was used to identify the molecular pathways and describe the biological processes of the transcript profiling data 34 . Pathway analyses were performed using Gene Set Enrichment Analysis tools and were based on differentially expressed genes in each treatment group including phototherapy, gene therapy and chemotherapy compared with sham controls. Differential expression was defined as multiple testing adjusted p values that are smaller than or equal to 0.05 and fold change greater than or equal to 1.5-fold by probes with the maximum intensity in each gene. The enrichment results with canonical pathway gene sets C2CP were reported and a false discovery rate (FDR) of 25% or less was used to select interesting gene sets for hypothesis generation.
Based on the GO analysis, the GO terms of 'biological process' that were significantly over-represented in each cluster of the heat maps are shown in Fig. 5b . The GO terms of the altered genes belong to multiple pathways mainly related with metabolism, intracellular transport mechanisms, receptor signalling, cell cycle and apoptosis, immune and defence response and transcription/translation processes. These observations confirm the distinct up-and downregulation of genes following the different therapeutic modalities, especially succeeding phototherapy.
We found that in response to phototherapy the molecular pathways involved were mainly regulated by genes controlling intracellular transport, such as membrane trafficking, whereas the mechanisms behind both gene therapy and chemotherapy approaches were mainly regulated by transcription (that is, chromatin organization) and metabolism (that is, metabolism of proteins, of amino acids, of nucleotides, of nitric oxide or of carbohydrates) ( Fig. 5b and Supplementary Fig. 26 ).
To identify key genes involved in CRC that could be altered in response to each therapy, we used MetaCore; an integrated software suited for functional analysis of microarrays, based on a high-quality, manually curated database of signalling and metabolic pathways. By clustering the GO data using disease biomarkers via the calculation of the p-value distribution of the differentially expressed genes in each treatment group, we were able to identify deregulated pathways in response to each therapy. A Venn diagram shows that only phototherapy alone alters more than 2,000 genes, including 14 key genes that are associated with CRC progression that are activated in response to stress or to external stimuli, such as metabolism, receptor signalling and defence mechanisms. (Fig. 5c and Supplementary Fig. 26 .) For example, PLG (plasminogen) whose activation leads to a decrease in apoptosis and tumour progression 35 is downregulated following phototherapy when compared with the sham, which is upregulated.
Another example is SFRP4 (secreted frizzled-related protein 4), which is associated with the Wnt signalling and that is downregulated in response to phototherapy. It is well known that an abnormal regulation of the Wnt signalling pathway plays a key role in the onset and progression of CRC, as this pathway is activated in colon cancer cells 36 . Another gene that is highly upregulated in response to phototherapy is ANK1 (ankyrin 1), which plays key roles in cytoskeleton remodelling and maintenance of specialized membrane domains.
When comparing all of the common genes and variants in the different treatment groups (Fig. 5c and Supplementary  Fig. 27 ), we found that the majority of genes related to CRC progression were mainly associated with intracellular transport (for example, CTNNA2, which is a structural constituent of cytoskeleton and cadherin binding and that we found highly repressed in the phototherapy group alone), receptor signalling (for example, EPHA1, which is protein-tyrosine kinase that has been implicated in colorectal carcinogenesis 37 and that we found slightly upregulated in the phototherapy group), or immune system (for example, DEFB119, which is a β-defensin and a diagnostic markers in CRC 38 that was highly repressed in the phototherapy group alone). The qPCR validation of the expression levels of these genes is depicted in Supplementary Fig. 28 . These results are in concordance with the microarray results and further confirm the reliability and accuracy of the array chip approach.
The molecular pathways that determine the effectiveness of antitumour response following a specific therapy are poorly understood.
Our profiling analysis allowed us to identify potential intermediaries of tumour response to therapy. By employing a network analysis methodology, we could classify and rank numerous cores that were related to response to therapy. Specifically, whole-gene expression analysis of tumours from treated mice suggests that phototherapy treatment leads to the repression and induction of a higher number of genes and variants when compared with gene therapy or chemotherapy. Molecular pathways that are mainly regulated by genes controlling intracellular transport, such as membrane trafficking, were 'turned on' in response to phototherapy, whereas transcription and metabolism mechanisms were stimulated following both gene therapy and chemotherapy. Moreover, the gene expression analysis revealed that the efficacy of the treatment is correlated with the number of genes altered; the phototherapy group is highly efficacious in reducing tumour size (Fig. 4d) and increasing mouse survival (Fig. 4e) while inducing the highest number of altered genes (Fig. 5c ).
Canonical pathway kinetics in local triple therapy
Gene expression data analysis provides insights into the contribution of each therapeutic modality to tumour abrogation. Nevertheless, the contribution of the combination of the three therapeutic modalities: gene therapy, chemotherapy and phototherapy, is a key element in studying the host response based on genome-wide microarray analysis. However, 15 days post-treatment with the tripletherapy hydrogel, the RNA in the excised tumours was completely degraded following irradiation (see Supplementary Fig. 29 ) and hence did not pass the quality check required for the microarray studies. Therefore, we conducted a series of in vivo experiments in which we followed the gene expression alteration succeeding triple therapy over time, providing information about the canonical pathway kinetics of the triple-therapy combination (Fig. 6) .
Interestingly, tumour genetic profiles of mice treated with the triple therapy change over time (Fig. 6a) . This is evident when we compare and contrast the altered genes in treated mice at 6, 24, 48 or 72 h. At the intersection of the genetic profiles of all the treatment groups there are more than 500 common genes (Fig. 6b) . These genes are mainly associated with apoptosis and survival (Beta-2 adrenergic receptor) as well as stress response (serotonin receptor HTR1A), immune system (MAPK signalling), chemotaxis (that is, CCL16, CCL20, CXCL16 and CCL25) and regulation of extracellular matrix (matrix metalloproteinase (MMP) family).
Based on the GO analysis, the GO terms of the altered genes change over time (Fig. 6c) and increase in number. At 6 h, the majority of the altered genes belong to pathways that are mainly related to metabolism, cell cycle and apoptosis (downregulation of caspase-10 and upregulation of death receptors DR3, 4 and 5) and immune and defence responses (upregulation of IL-22, IL-1 and IL-4). At 24 h, there is a significant increase in altered genes related to metabolism (upregulation of cytochromes (CYPs) and hydroxysteroid dehydrogenases (HSDs)) and transcription (upregulation of histones H1, H2 and G-protein). At 48 and 72 h, the molecular pathways controlling the tumour cells shift completely to processes related to receptor signalling (downregulation of Ephrin receptors, EGFR and VEGF, this last due to the Avastin action, which neutralizes VEGF and blocks its signal transduction) and regulation of extracellular matrix (upregulation of E-cadherin, plasmin and MMPs, and downregulation of collagen III and IV). From 6 h to 72 h, the number of altered genes also changes from 209 to 3,589, which correlates with the maximum therapeutic efficacy observed after 72 h using the local triple-therapy combination (see Fig. 4 ). This proves that the genetic profile is determined by the therapeutic modality.
Taken together, the wide genome array assays from tumours in response to each of the single therapeutic modalities and especially to the triple-combination therapy provide potential biomarkers for gene/drug/phototherapy in clinical application. The biomarkers identified herein via quantitative gene expression analysis may be used in the future to better design materials that can target specific genes/pathways to achieve better clinical outcome based on prognosis analysis and correlations between preclinical studies and patient-derived samples to choose the optimal disease-associated biomarkers. A comprehensive scrutiny of the genes in the tumour microenvironment in response to therapy as the ones realized herein should further drive the discussion on what 'cargos' a material should contain in light of the observed tumour microenvironment characteristics and response to therapy.
Outlook
Our work presents a rational treatment strategy following a comprehensive scrutiny of the tumour microenvironment and host response to different therapeutic modalities based on genome-wide microarray analysis. The triple-therapy patch (that is, gene therapy, chemotherapy and phototherapy combination) synergistically abrogates the tumour, facilitating complete prevention of colon cancer recurrence following resection, and complete tumour remission when applied to non-resected tumours. Our results demonstrate the superiority of local compared with systemic administration or intratumoral injections both in terms of tumour shrinkage and survival rate. We identified the molecular and genetic pathways triggered in response to the three therapeutic modalities-phototherapy, gene therapy and chemotherapyby tumour gene expression profiling in treated mice. Tumour genetic profiles of triple-therapy-treated mice are associated with an increased number of altered genes, which correlates with therapeutic efficacy as measured by tumour size. Hence, biomaterials-based local therapy provides a platform for efficient cancer treatment and for the discovery of new therapeutic targets. Follow-up studies in large preclinical models would exploit colonoscopy equipment to deliver the material directly to the colonic tumour while enabling the material to cure in situ. This delivery approach would eliminate issues associated with laser penetration, as photothermal irradiation would occur directly at the tumour site. Utilizing minimally invasive techniques (for example, colonoscopy) to apply the triple-therapy platform and evaluate its efficacy would potentially improve clinical procedures and therapeutic outcomes.
Methods
Methods and any associated references are available in the online version of the paper.
analysed using R 2.15.3. Scatter plots were also made by R 2.15.3. Heat maps were created by Genesis 1.7.6 based on Pearson correlation coefficients of each replicate per condition.
Gene ontology and pathway analysis. Pathway analyses were performed using Gene Set Enrichment Analysis tool v2.0.13 (GSEA2-2.0.13) 40, 41 . The analyses were based on differentially expressed genes in each treatment group including phototherapy, gene therapy, chemotherapy or the triple-therapy combination compared with sham controls. Differential expression was defined as multiple testing adjusted p values smaller than or equal to 0.05 and fold change greater than or equal to 1.5-fold by probes with the maximum intensity in each gene. The enrichment results with canonical pathway gene sets C2CP were reported. FDR 25% or less was used to select interesting gene sets for hypothesis generation.
Statistics. Differences between groups were examined using a two-tailed Student's t-test, two-way analysis of variance or a Log-Rank Mantel-Cox test through the SPSS statistical package (version 23, SPSS). All error bars used in this report are mean ± s.d. of at least three independent experiments. Statistically significant p values are indicated in figures and/or legends as * * * , P < 0.005; * * , P < 0.01; * , P < 0.05. All in vivo experiments used five mice per treatment group. A power analysis was performed using G * Power software (version 3.1.9.2) to determine sample size. For n = 5 mice per group the power is 90% with a signal-to-noise ratio of 2.4, assuming a 5% significance level and a two-sided test. The signal/noise ratio of 2.4 corresponds to a 6.1% background signal. No randomization or blind events were used in animal studies.
